Free Trial

Kalaris Therapeutics (KLRS) Stock Forecast & Price Target

Kalaris Therapeutics logo
$2.69 +0.01 (+0.37%)
As of 08/1/2025 04:00 PM Eastern

Kalaris Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
0

Based on 1 Wall Street analysts who have issued ratings for Kalaris Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 1 analysts, 1 has given a hold rating for KLRS.

Consensus Price Target

$3.00
11.52% Upside
According to the 1 analysts' twelve-month price targets for Kalaris Therapeutics, the average price target is $3.00. The highest price target for KLRS is $3.00, while the lowest price target for KLRS is $3.00. The average price target represents a forecasted upside of 11.52% from the current price of $2.69.
Get the Latest News and Ratings for KLRS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Kalaris Therapeutics and its competitors.

Sign Up

KLRS Analyst Ratings Over Time

TypeCurrent Forecast
8/2/24 to 8/2/25
1 Month Ago
7/3/24 to 7/3/25
3 Months Ago
5/4/24 to 5/4/25
1 Year Ago
8/3/23 to 8/2/24
Strong Buy
0 Strong Buy rating(s)
N/A N/A N/A
Buy
0 Buy rating(s)
N/A N/A N/A
Hold
1 Hold rating(s)
N/A N/A N/A
Sell
0 Sell rating(s)
N/A N/A N/A
Consensus Price Target$3.00N/AN/AN/A
Forecasted Upside11.52% UpsideN/AN/AN/A
Consensus Rating
Hold
N/AN/AN/A

KLRS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

KLRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Kalaris Therapeutics Stock vs. The Competition

TypeKalaris TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.81
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside11.52% Upside10,407.36% Upside14.55% Upside
News Sentiment Rating
Neutral News

See Recent KLRS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/23/2025Piper Sandler
2 of 5 stars
Biren Amin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$3.00+16.73%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 04:28 PM ET.


KLRS Forecast - Frequently Asked Questions

According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for Kalaris Therapeutics is $3.00, with a high forecast of $3.00 and a low forecast of $3.00.

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kalaris Therapeutics in the last year. There is currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KLRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KLRS, but not buy additional shares or sell existing shares.

According to analysts, Kalaris Therapeutics's stock has a predicted upside of 11.52% based on their 12-month stock forecasts.

Kalaris Therapeutics has been rated by research analysts at Piper Sandler in the past 90 days.

Analysts like Kalaris Therapeutics less than other "medical" companies. The consensus rating for Kalaris Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how KLRS compares to other companies.


This page (NASDAQ:KLRS) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners